TNXP

Tonix Pharmaceuticals Holding Corp

5.10

Oct 30 • 3:59 PM ET -0.18 (-3.41%)

5.14

Aftermarket • 7:56 PM ET +0.04 (0.77%)

Healthcare Biotechnology USA Micro NASD

Peers: VNDA AXSM DWTX RLMD HRMY CING MNOV ANRO TRVI VTGN

| Held by: VTI IWM VXF FESM VTWO IWN IWC PRFZ VTWV DFMC

Scroll to Statements

Index	RUT
Market Cap	87.47M
Enterprise Value	-87.49M
Income	-159.67M
Sales	29.10M
Book/sh	13.24
Cash/sh	10.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	142
IPO	Feb 03, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	3.01
P/B	0.39
P/C	0.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-3.01
Quick Ratio	6.46
Current Ratio	6.61
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-12.93
EPS next Y	-6.41
EPS next Q	-2.39
EPS this Y	32.89%
EPS next Y	34.41%
EPS next 5Y	36.41%
EPS past 3/5Y	93.94% 86.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.71%
Sales Y/Y TTM	196.02%
EPS Q/Q	36.82%
Sales Q/Q	577.88%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	7.66% 75.38%

Insider Own	0.36%
Insider Trans	30.46%
Inst Own	56.60%
Inst Trans	9.44%
ROA	-72.34%
ROE	-81.82%
ROIC	-71.50%
Gross Margin	76.53%
Oper. Margin	-568.43%
Profit Margin	-548.64%
SMA20	-17.21%
SMA50	-46.51%
SMA200	-59.10%
Trades

Shs Outstand	17.15M
Shs Float	17.09M
Short Float	17.21%
Short Ratio	4.53
Short Interest	2.94M
52W High	20.56 -75.19%
52W Low	5.01 1.80%
Volatility	6.25% 8.05%
ATR (14)	0.48
RSI (14)	17.45
Beta	1.85
Rel Volume	0.87
Avg Volume	649.37K
Volume	567,234

Perf Week	-1.35%
Perf Month	-44.75%
Perf Quarter	-52.18%
Perf Half Y	-62.50%
Perf YTD	-67.35%
Perf Year	-71.76%
Perf 3Y	-99.72%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	39.00
Prev Close	5.28
Price	5.10
Change %	-3.41%

Consensus

Strong Buy

Avg. Price Target

$39.00

Implied Upside

+664.7%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 26, 2026	Initiated	CCanaccord Genuity	Buy	$18	+252.9%
Jun 25, 2026	Initiated	RRaymond James	Strong Buy	$26	+409.8%
May 04, 2026	Initiated	TTD Cowen	Buy	$22	+331.4%
Apr 18, 2022	Initiated	NNoble Capital Markets	Outperform
Apr 18, 2019	Upgrade	RROTH Capital	Neutral → Buy	$4	-21.6%
Aug 18, 2017	Upgrade	RROTH Capital	Neutral → Buy	$6	+17.6%
Sep 07, 2016	Downgrade	RROTH Capital	Buy → Neutral
Feb 17, 2016	Reiterated	OOppenheimer	Outperform	$18 → $10	+96.1%
Nov 04, 2015	Initiated	CCantor Fitzgerald	Buy
Jun 12, 2015	Initiated	OOppenheimer	Outperform	$18	+252.9%
Feb 17, 2015	Reiterated	RROTH Capital	Buy	$10 → $12	+135.3%
Sep 29, 2014	Reiterated	RROTH Capital	Buy	$17 → $10	+96.1%

Oct-27-26 07:00AM	Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain (GlobeNewswire)
Oct-26-26 07:00AM	Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 (GlobeNewswire)
Oct-19-26 07:00AM	Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA at the IASP 2026 World Congress on Pain (GlobeNewswire) -5.13%
Oct-15-26 07:00AM	Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026 (GlobeNewswire)
Sep-22-26 07:00AM	Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA (GlobeNewswire)
07:00AM	Loading…
Sep-08-26 07:00AM	Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer (GlobeNewswire)
Sep-02-26 07:00AM	Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference (GlobeNewswire)
Aug-10-26 05:01PM	Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... (GuruFocus.com)
07:00AM	Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-26 07:00AM	Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-03-26 07:00AM	Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. (GlobeNewswire) +6.54%
Jul-27-26 07:00AM	Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 (GlobeNewswire)
Jul-15-26 09:05AM	Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models (GlobeNewswire)
Jul-13-26 08:21AM	Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) (InvestorsHub) -6.58%
07:00AM	Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA (GlobeNewswire)
07:25AM	Loading…
Jun-29-26 07:25AM	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Jun-25-26 09:34AM	Qualcomm upgrade, Intel initiation among today's top calls on Wall Street (The Fly)
Jun-11-26 07:00AM	Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 (GlobeNewswire)
Jun-08-26 09:46AM	Why Is TNXP Stock Rising Today? (Stocktwits) +5.78%
07:00AM	Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA, Expanding Total Commercial Coverage to ~52 Million U.S. Lives (GlobeNewswire)
May-28-26 04:30PM	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-27-26 07:00AM	Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology (GlobeNewswire)
May-26-26 07:00AM	Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting (GlobeNewswire)
May-14-26 07:00AM	Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 (GlobeNewswire)
May-12-26 04:30PM	Tonix Pharmaceuticals to Participate in Two Investor Conferences in May (GlobeNewswire) -5.88%
May-11-26 04:30PM	Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
May-06-26 07:00AM	Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA, Providing Access for ~35 Million U.S. Patients (GlobeNewswire) +8.81%
Apr-29-26 07:00AM	Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University (GlobeNewswire)
Apr-23-26 07:00AM	Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Apr-15-26 07:00AM	Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development (GlobeNewswire) +7.42%
07:00AM	Loading…
Mar-31-26 07:00AM	Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 (GlobeNewswire) +14.30%
Mar-26-26 07:00AM	Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain (GlobeNewswire) -8.33%
Mar-23-26 04:32PM	Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 (GlobeNewswire) +7.20%
Mar-18-26 04:58PM	Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 (GlobeNewswire) -5.15% +11.13%
Mar-17-26 04:35PM	Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire) +10.32%
Mar-12-26 05:30PM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (GlobeNewswire)
Mar-10-26 08:00AM	Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Mar-09-26 04:30PM	Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting (GlobeNewswire)
04:30PM	Tonix Pharmaceuticals Presented Data on TONMYA in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting (GlobeNewswire)
Mar-05-26 04:15PM	Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development (GlobeNewswire)
Mar-03-26 04:30PM	Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting (GlobeNewswire)
07:04AM	Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting (Benzinga)
06:00AM	Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market (GlobeNewswire)
Feb-25-26 07:00AM	Tonix Pharmaceuticals to Participate in Two Investor Conferences in March (GlobeNewswire)
Jan-30-26 07:00AM	Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit (GlobeNewswire) -5.38%
Jan-06-26 07:00AM	Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 (GlobeNewswire)
Dec-30-25 08:00AM	Tonix prices 615,025 shares at $16.26 in registered direct offering (TipRanks)
Dec-29-25 07:57AM	Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering (GlobeNewswire)
07:45AM	Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) (GlobeNewswire)
Dec-16-25 07:00AM	Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University (GlobeNewswire)
Dec-09-25 07:00AM	Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel (GlobeNewswire)
Nov-24-25 07:00AM	Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder (GlobeNewswire) -11.27%
Nov-17-25 07:00AM	Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment (GlobeNewswire) +5.69%
Nov-10-25 04:15PM	Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Nov-06-25 07:00AM	Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-04-25 07:00AM	Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection (GlobeNewswire) -6.53%
Oct-29-25 11:57AM	Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data (Insider Monkey)
Oct-28-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025 (GlobeNewswire)
Oct-27-25 07:00AM	Tonix Pharmaceuticals Presented Data on Tonmya (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Oct-22-25 07:00AM	Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital (GlobeNewswire)
Oct-21-25 07:00AM	Tonix Pharmaceuticals to Present Poster on Tonmya at the 2025 American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Oct-17-25 07:00AM	Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025 (GlobeNewswire)
Oct-14-25 07:00AM	Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation (GlobeNewswire)
Oct-09-25 07:00AM	Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 (GlobeNewswire)
Sep-30-25 08:30AM	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access (GlobeNewswire)
03:46AM	Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? (Pharma Voice)
Sep-29-25 07:00AM	Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 (GlobeNewswire)
Sep-18-25 08:00AM	Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder (GlobeNewswire)
Sep-17-25 07:00AM	Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) (GlobeNewswire)
Sep-08-25 07:00AM	Tonix Pharmaceuticals Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025 (GlobeNewswire)
Aug-28-25 07:00AM	Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-18-25 01:07PM	FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide (Investor's Business Daily) -21.97%
09:45AM	Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years (Benzinga)
09:04AM	FDA Approves New Fibromyalgia Drug, Tonix Shares Climb (Investor's Business Daily)
05:02AM	FDA approves Tonixs Tonmya to treat fibromyalgia (Pharmaceutical Technology)
Aug-15-25 03:44PM	Tonix Pharmaceuticals Announces FDA Approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia (GlobeNewswire) -13.81%
Aug-11-25 04:15PM	Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire) +32.89%
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire)
Jul-21-25 07:00AM	Tonix Pharmaceuticals Announces the Launch of the "Move Fibro Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia (GlobeNewswire)
Jul-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire) +10.43%
Jul-09-25 04:01PM	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine (GlobeNewswire) +7.87%
Jul-07-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire)
Jul-02-25 07:00AM	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models (GlobeNewswire) -5.71%
Jul-01-25 07:23AM	Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes (TipRanks)
Jun-30-25 07:00AM	Tonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-16-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire) +15.60%
Jun-13-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors (GlobeNewswire) -7.41%
Jun-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention (GlobeNewswire)
Jun-05-25 07:00AM	Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire)
May-22-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase (GlobeNewswire) -6.81%
May-21-25 07:00AM	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction (GlobeNewswire) -5.25%
May-14-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations (GlobeNewswire) +9.42%
May-12-25 04:30PM	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire) +5.16%
Apr-29-25 09:05AM	Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire)
Apr-24-25 07:55AM	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 (GlobeNewswire) -6.71%
Apr-10-25 09:24AM	Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? (Insider Monkey)
Apr-09-25 07:00AM	Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies (GlobeNewswire) -9.64%
Apr-07-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting (GlobeNewswire) +13.81%
Apr-02-25 07:00AM	Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEDERMAN SETH	Chief Executive Officer	Aug 27 '26	Buy	13.79	2,000	27,580	11,005	Aug 31 08:00 AM
BAGGER RICHARD H	Director	Aug 20 '26	Buy	12.60	1,000	12,600	1,000	Aug 24 08:00 AM
Taylor Carolyn E.	Director	Jun 12 '26	Buy	10.55	1,415	14,928	1,833	Jun 15 07:00 AM
Stillwell Richard Newcomb	Director	Jun 08 '26	Buy	11.65	5,000	58,250	5,000	Jun 09 05:30 PM
LEDERMAN SETH	Chief Executive Officer	Jun 09 '26	Buy	11.79	5,000	58,950	9,005	Jun 09 05:30 PM
LEDERMAN SETH	Chief Executive Officer	Mar 31 '26	Buy	12.62	5,000	63,100	20,001	Apr 01 09:31 AM
LEDERMAN SETH	Chief Executive Officer	Mar 18 '26	Buy	14.89	15,000	223,350	15,001	Mar 18 05:03 PM

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Co-FounderDr. Seth Lederman M.D.

CFO & TreasurerMr. Bradley Saenger CPA

Chief Operating OfficerMrs. Jessica Edgar Morris

SecretaryDr. Gregory M. Sullivan M.D.

M.Sc.Ms. Siobhan Fogarty B.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNXP

Tonix Pharmaceuticals Holding Corp

Upgrade your Finviz experience